Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

3964 - Radium-223 (Ra-223) therapy after abiraterone (Abi): analysis of symptomatic skeletal events (SSEs) in an international early access program (iEAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)


22 Oct 2018


Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care


Cytotoxic Therapy;  Radiation Oncology

Tumour Site

Prostate Cancer


Kurt Miller


Annals of Oncology (2018) 29 (suppl_8): viii271-viii302. 10.1093/annonc/mdy284


K. Miller1, D. Heinrich2, J.M. O'Sullivan3, J. Carles4, M. Wirth5, S. Nilsson6, L. Huang7, J. Kalinovsky8, A. Heidenreich9, F. Saad10

Author affiliations

  • 1 Urology, Charité Berlin, 12200 - Berlin/DE
  • 2 Oncology, Akershus University Hospital, Oslo/NO
  • 3 Centre For Cancer Research & Cell Biology, Queen's University Belfast, Belfast/GB
  • 4 Medical Oncology, Vall d'Hebron University Hospital, Barcelona/ES
  • 5 Urology, University Hospital Carl Gustav Carus, Dresden/DE
  • 6 Oncology-pathology, Karolinska University Hospital, Stockholm/SE
  • 7 Statistics, Bayer HealthCare Pharmaceuticals, Whippany/US
  • 8 Medical Oncology, Bayer Consumer Care AG, Basel/CH
  • 9 Urology, University Hospital Cologne, Cologne/DE
  • 10 Urology, University of Montreal Hospital Center, Montreal/CA


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3964


Ra-223 phase 3 study (ALSYMPCA) was conducted before Abi became available. The Ra-223 iEAP study included Abi-treated pts. Here, we assessed SSEs, OS and bone health agent (BHA) use in Ra-223-treated pts who received Abi as a prior treatment.


This open-label, single-arm trial enrolled pts with bone-predominant mCRPC (≥2 bone metastases [BM]). Pts who received prior anti-cancer therapies were included; use of BHAs (bisphosphonates and denosumab) was permitted before/during the study. Median follow-up was 7.5 mo. Baseline characteristics, SSEs, (EBRT, symptomatic pathological fractures, spinal cord compression or surgical intervention) and OS were analysed descriptively for pts who completed prior Abi therapy and Abi-naïve pts.


Of 708 mCRPC pts, 85% of prior Abi and 36% of Abi-naïve pts had previously received docetaxel (Table). During Ra-223 therapy, 14% and 17% of pts received concomitant bisphosphonates and 20% and 17% concomitant denosumab in the prior Abi and Abi-naïve groups, respectively. Median time since BM diagnosis and start of Ra-223 was 37 and 21 mo in the prior Abi and Abi-naïve pts, respectively. Median OS was 15.9 mo overall (11.2 mo for prior Abi and 17.1 mo for Abi-naïve pts). More pts had SSEs in the prior Abi (26%) than the Abi-naïve group (14%); proportions of treatment-emergent fractures were similar in both groups (4% and 3%, respectively), as was incidence of pathological bone fractures (5% for both).Table: 824P

Prior Abi (n = 223)Abi naïve (n = 321)Overall population (n = 708)
ECOG: 0 and 1, n (%)195 (87)273 (85)618 (87)
PSA, median (µg/l)290100143
ALP median (U/l)169148150
Time since diagnosis of prostate cancer, median (months)815364
Time between diagnosis of prostate cancer and bone metastases, median (months)261119
Time from diagnosis of bone metastases to Ra-223 treatment, median (months)372126
Prior docetaxel, n (%)189 (85)117 (36)423 (60)
Prior bisphosphonate, n (%)19 (9)13 (4)48 (7)
Prior denosumab, n (%)6 (3)6 (2)14 (2)
Concomitant bisphosphonates, n (%)30 (14)56 (17)122 (17)
Concomitant denosumab, n (%)44 (20)53 (17)129 (18)
Total Ra-223 injections, median (range)5.0 (1–6)6.0 (1–6)6.0 (1–6)
OS, median (95% CI) (months)11.2 (9.7,13.5)17.1 (12.7, Not available)15.9 (13.4, Not available)
Any SSE, n (%)58 (26)45 (14)145 (21)
Treatment-emergent fracture, n (%)8 (4)11 (3)31 (4)
Experienced pathological bone fracture, n (%)12 (5)15 (5)39 (6)


Pts in the prior Abi group had a longer time from diagnosis of BM to Ra-223 initiation. These pts seem more advanced, as reflected by higher median baseline PSA and more pts with prior docetaxel therapy. BHAs appear to be under-utilised in clinical practice in this pt population. A similar rate of pathological and non-pathological fractures was reported in Ra-223-treated pts regardless of prior use of Abi.

Clinical trial identification


Legal entity responsible for the study




Editorial Acknowledgement

Medical writing support was provided by Rebecca Hopkins, BSc, of Scion, London UK, funded by Bayer.


K. Miller: Honoraria, consultation fees: Amgen, Bayer, BMS, Ferring, Janssen, MSD, Novartis, Pfizer, Roche, Sotio, Takeda, Tolmar. D. Heinrich: Speaker, consultancy honoraries: Bayer, Janssen-Cilaq (Johnson & Johnson) J.M. O’Sullivan: Advisory boards, speaker's bureau: Bayer, Janssen, Sanofi. J. Carles: Consultant, Scientific advisory board attendee: Johnson & Johnson, Astellas, Bayer, Amgen, Pfizer, BMS; Speaker's bureau: Bayer, Johnson & Johnson. M. Wirth: Advisory board:Vital GmbH. S. Nilsson: Advisory boards, remuneration: Bayer. L. Huang, J. Kalinovsky: Employee: Bayer Healthcare. A. Heidenreich: Honoraria, advisory board: Amgen, Astellas, Bayer, Ferring, Ipsen, Janssen, Pfizer, Takeda, Sanofi. F. Saad: Consultant, Research grants: Bayer, Amgen, Astellas, Jansssen, Sanofi, AstraZeneca.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.